Clinical Trials on Localized Cutaneous Leishmaniasis in United States

Total 951 results

Drugs for Neglected Diseases
Wellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...

Completed

Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

Visceral Leishmaniasis | Cutaneous Leishmaniases

United Kingdom
University of Brasilia

Completed

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients (Sbold)

Localized Cutaneous Leishmaniasis

Brazil
University of York
Medical Research Council; Department for International Development, United...

Completed

A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies (LEISHChallenge)

Leishmaniasis | Cutaneous Leishmaniases | Insect Bites

United Kingdom
Knight Therapeutics (USA) Inc

Completed

Miltefosine to Treat Mucocutaneous Leishmaniasis

Cutaneous Leishmaniasis | Mucosal Leishmaniasis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

Cutaneous Leishmaniasis

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Terminated

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

Cutaneous Leishmaniasis

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Medical Center

Completed

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

United States
U.S. Army Medical Research and Development Command
InBios International, Inc.

Completed

Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis

Skin Diseases

United States
Nielsen BioSciences, Inc.
U.S. Army Medical Research and Development Command

Completed

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

Cutaneous Leishmaniasis

United States
University of California, San Francisco

No longer available

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Leishmaniasis, Cutaneous | Leishmaniasis, Mucocutaneous

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military...

Terminated

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis (WRNMMC)

Leishmaniasis, Cutaneous

United States
U.S. Army Medical Research and Development Command

No longer available

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

Leishmaniasis, Cutaneous

United States
University of York
Medical Research Council

Completed

A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol (FLYBITE)

Leishmaniasis, Cutaneous | Insect Bites

United Kingdom
IDRI
Bill and Melinda Gates Foundation

Completed

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

Visceral Leishmaniasis

United States
Northwestern University

Terminated

Molecular Effects of Topical Calcipotriene on Morphea

Morphea | Localized Scleroderma

United States
Castle Creek Biosciences, LLC.

Terminated

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Scleroderma, Localized | Morphea | Scleroderma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Clinical Investigation of Infections Due to Leishmanial Parasites

Leishmaniasis | Leishmaniasis, Visceral

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma AJCC v8 | Clinical Stage... and other conditions

United States
Knight Therapeutics (USA) Inc

Recruiting

Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

Leishmaniasis or Other Uses of Miltefosine

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Mycosis Fungoides | Localized Skin Lesion

United States
University of California, Davis

Active, not recruiting

Aesthetic Outcome of Electrodesiccation and Curettage vs Excision With Complex Linear Closure

Cutaneous Surgery

United States
David Weinstein

Terminated

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

Cutaneous Lupus

United States
Cutera Inc.

Terminated

Thigh Circumference Reduction Study

Reduction of Localized Excess Fat

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Natural History of Severe Allergic Inflammation and Reactions

PGM3 Deficiency | Eosinophilic and/or Atopic Dermatitis | OSMR Deficiency | Primary Localized Cutaneous Amyloidosis | Hereditary Alpha-tryptasemia

United States
Wake Forest University Health Sciences

Active, not recruiting

Cutaneous Lupus Medication Experience Study

Cutaneous Lupus

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Carlo Contreras

Recruiting

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Metastatic Melanoma | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma Stage I | Cutaneous T-cell Lymphoma Stage II | Cutaneous T-cell Lymphoma Stage III | Cutaneous T-cell Lymphoma Stage IV

United States
Mayo Clinic

Active, not recruiting

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center

Recruiting

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Malignant Solid Neoplasm | Colitis | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditions

United States
John Reneau

Active, not recruiting

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
University of Pennsylvania
Celgene Corporation

Completed

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States
Johns Hopkins University

Completed

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Cutaneous Toxicity From ICI Therapy

United States
Michael M. Pham

Terminated

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

Systemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditions

United States
Ben Chong
Daavlin Corporation

Completed

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

Cutaneous Lupus Erythematosus

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Metastatic Malignant Neoplasm in the Brain | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
UMC Utrecht
Boehringer Ingelheim; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (UPSIDE)

Systemic Sclerosis | Scleroderma, Diffuse | Mycophenolate Mofetil | Scleroderma | Autologous Stem Cell Transplantation | Cyclophosphamide | Systemic Scleroses, Diffuse | Treatment Strategy

Italy, Switzerland, Netherlands, Sweden, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study (DIET)

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Richard Wu
Iovance Biotherapeutics, Inc.

Active, not recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Locally Advanced Melanoma | Stage IV Melanoma | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States

Clinical Trials on Localized Cutaneous Leishmaniasis in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations